Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Muscular Atrophy × Olanzapine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 13 Nausea 13 Neoplasms 7 Hematologic Neoplasms 5 Breast Neoplasms 3 Anorexia 3 Squamous Cell Carcinoma of Head and Neck 2 Lung Neoplasms 2 Cachexia 2 Weight Loss 1 Testicular Neoplasms 1 Stomach Neoplasms 1 Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1 Sedentary Behavior 1 Radiation Injuries 1 Prosthesis Failure 1 Postoperative Nausea and Vomiting 1 Pain 1 Opioid-Related Disorders 1 Nutrition Disorders 1 Neoplasms, Plasma Cell 1 Neoplasms, Germ Cell and Embryonal 1 Muscular Atrophy 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Insulin Resistance 1 Hyperlipidemias 1 Hyperglycemia 1 Gynecologic Cancer 1 Gliosarcoma 1

Interventions

rimabotulinumtoxinB 1 ostarine 1 Standard of Care 1 Olanzapine 1 Enteral Nutrition 1 Eicosapentaenoic Acid 1 Diet Therapy 1 Cyproheptadine 1 Creatine 1 Carnitine 1 Botulinum Toxins, Type A 1 Acetylcysteine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06175273 2025-09-18

POINT

University of Kentucky

Phase 2/3 Completed

Muscular Atrophy, Neoplasms, Child Nutrition Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡